TAK-375 Takeda

Curr Opin Investig Drugs. 2005 Jan;6(1):114-21.

Abstract

TAK-375 (Ramelteon), a melatonin ML1/MT1 receptor agonist for the potential treatment of primary insomnia, is being developed by Takeda. Takeda submitted an NDA to the FDA for TAK-375 in September 2004.

Publication types

  • Review

MeSH terms

  • Animals
  • Clinical Trials as Topic
  • Humans
  • Indenes* / adverse effects
  • Indenes* / pharmacokinetics
  • Indenes* / therapeutic use
  • Receptor, Melatonin, MT1 / agonists
  • Sleep Wake Disorders / drug therapy*
  • Sleep Wake Disorders / metabolism

Substances

  • Indenes
  • Receptor, Melatonin, MT1
  • ramelteon